Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MCLA-129 by Merus for Paranasal Sinus And Nasal Cavity Cancer: Likelihood of Approval
MCLA-129 is under clinical development by Merus and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer. According...
MCLA-129 by Merus for Oropharyngeal Cancer: Likelihood of Approval
MCLA-129 is under clinical development by Merus and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...
MCLA-129 by Merus for Laryngeal Cancer: Likelihood of Approval
MCLA-129 is under clinical development by Merus and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Merus's MCLA-129?
MCLA-129 is a monoclonal antibody commercialized by Merus, with a leading Phase II program in Solid Tumor. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Merus's MCLA-129?
MCLA-129 is a monoclonal antibody commercialized by Merus, with a leading Phase II program in Esophageal Squamous Cell Carcinoma (ESCC)....